Summary: Both cell therapy innovators and manufacturing organizations are employing novel technologies and methodologies to adapt to an accelerated and evolving clinical landscape

Summary: This roundtable is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.

Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.

Summary: Catalent has made significant investments in the cell and gene therapy space with strategic acquisitions and commitment to grow and innovate.

Summary: Catalent has made significant investments in capacity expansions to meet the growing demand of our customers.

Summary: This executive summary details why maintaining a strategic view of the production-scale from early stages of development helps accelerate the time-to-market, drives process efficiencies, and reduces costs.

Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities...

Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based...

Summary: In this on-demand webinar from the 2020 CPhI Festival of Pharma, panelists discuss innovative technologies and their adoption for cell and gene therapies.